Oct. 16 at 3:54 PM
$PSNL
Personalis is still very under the radar and the MRD opportunity isn’t fully appreciated by Wall Street. This is going to change.
Again, I am a physician and have been studying the ctDNA (liquid biopsy) opportunity for many years. Personalis will reach
$50 per share, then eventually break through
$100 the same way
$NTRA did once Signatera gained reimbursement and sales traction. NeXT Personal is a superior product and I believe
$TEM will prove to be a phenomenal commercial partner with potential triple digit sales growth of NeXT Personal. Next year will also be exciting as Colorectal cancer moves closer to reimbursement.
Then there is eventual overseas expansion but we’ll save that discussion for a later date.
I clearly believe that those who hold
$PSNL shares long term will build substantial wealth. But more importantly, Personalis investors are strongly supporting a company whose platform will save and extend the lives of so many people.
Hold your shares tight.
